The United States of America, As Represented by the Secretary, Department of Health and Human Services

Fred Hutchinson Cancer Center

Marie Pancera

Baoshan Zhang

Michael Gordon Joyce

Yongping Yang

Ivelin Georgiev

Guillaume Stewart-Jones

Mallika Sastry

Peter D Kwong

Barney S Graham

Tongqing Zhou

Gwo-Yu Chuang

Aliaksandr Druz

Man Chen

Jason Gorman

Cinque Soto

John R Mascola

Ulrich Baxa

Masaru Kanekiyo

Cheng Cheng

Jason Scott McLellan

Jeffrey C Boyington

Wing-Pui Kong

Yaroslav Tsybovsky

Gilad Ofek

Li Ou

Paul Thomas

Joseph Van Galen

Lei Chen

Sanjay Srivatsan

Emily Rundlet

Priyamvada Acharya

Rita Chen

John Mascola

Rebecca M Lynch

Connor Weidle

Jason S Mclellan

Ivelin Stefanov Georgiev

Rebecca Lynch

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens.

Circumsporozoite proteins with increased expression in mammalian cells

Substitutions-modified prefusion RSV F proteins and their use

Growing community of inventors

Seattle, WA, United States of America

Marie Pancera